Cannsun has production, manufacturing and distribution throughout South Africa, Europe, Japan and Thailand. Our mission is to create natural formulations of adaptogens, cosmetics and cannabinoid products for the health and wellbeing of people across the world.

European Union

  • Working interest position in a EUGMP production and manufacturing facility, products include: CBD adaptogens, cosmetics & herbal medicines
  • Access to 11,000 pharmacies, 35,000 doctors & 100 wholesalers in Greece and sales to over 21 countries in Europe, Asia & Africa
  • Collaboration with University of Patras and Thessaloniki for R&D utilizing cannabinoid product development

South Africa

  • Africas largest medical cannabis cultivation license on 23-hectares with greenhouse and processing facilities (both GACP & South African GMP certified)
  • Phase 1: Complete 6500 m2 Facility under flower with greenhouse and processing facilities.
  • Phase 2: 15,000 m2 outdoor grow commenced November 2020 with harvest expected April 2021
  • BBBEE compliant, increasing participation of South African labor in economic activities: BBBEE Level 2 Company.

ASEAN

  • Thailand: Own and operate a GMP production and manufacturing facility for cannabinoid extraction development of adaptogens and cosmetics.
  • MOU with Mahasarakham University to develop cannabis genetics and Udon Thani Hospital to develop THC and CBD formulations for Clinical Trials relating to liver cancer
  • Malaysia: distribution of Cannsun products in Malaysia with application process in place to potentially distribute pharmaceutical products in late 2020
  • Japan: Distribution partnerships of CBD products – adaptogens, cosmetics and other botanical medicines

Lesotho

  • Alpine: 1 cultivation license awarded, 1.5 hectare Phase 1 development, construction currently underway
  • BBBEE complaint, increasing participation of South African labor in economic activities
TOP